Background & objectives: Tuberculosis (TB) is a public health problem worldwide. Rapid and accurate diagnosis of tuberculosis is crucial to facilitate early treatment of infectious cases and to reduce its spread. The present study was aimed to evaluation of 16 kDa antigen as a serodiagnostic tool in pulmonary and extra-pulmonary tuberculosis patients in an effort to improve diagnostic algorithm for tuberculosis.
TB diagnosis largely depends upon clinical examination and radiographic findings, mainly confirmed by sputum smear microscopy and bacterial culture 3 . Many alternative methodologies have been applied in TB diagnosis, such as PCR and cell-mediated immune response reactions 4 . These methods require trained personnel and specific laboratory conditions, which hinder their implementation in many areas of high TB endemicity.
Extra-pulmonary TB (EPTB) remains an important diagnostic and therapeutic problem. The diagnosis of extra-pulmonary tuberculosis is challenging due to the paucibacillary nature of the specimens, inability to access the site of disease activity, the lack of adequate sample volumes and the presence of inhibitors that undermine the performance of nucleic acid amplification-based techniques. Serological tests may prove useful with the advantages of speed, technical simplicity, possible adaptation towards point-of-care formats and low cost 5, 6 .
The availability of numerous well characterized M. tuberculosis proteins has revived interest in the serological diagnosis of tuberculosis. Several promising antigens have been reported such as 16 kDa, 45 kDa, antigen 85 complex (30 kDa), 65 kDa Hsp, 88 kDa, 38 kDa, etc 8 . Antibody response to the 38 kDa in pulmonary TB has been extensively studied, and there are a few reports about the utility of the 16 kDa-based serological tests in pulmonary and extrapulmonary TB [7] [8] [9] .
The aim of the present study was to explore the serodiagnostic potential of 16 kDa (HspX, Rv2031c, or α-crystalline) antigen in different groups of tuberculosis patients. 16 kDa is an immunodominant antigen that is recognized by the majority of patients with active tuberculosis 10 . Production of Rv2031c appears to increase as the bacteria go into the metabolically resting stage and decreases as they revert to exponential growth 11 , thus providing a constant source of antigen in cultures and possibly in vivo.
Material & Methods
A total of 347 subjects (age range= 18 to 65 yr, male= 235, female= 112) were recruited between June 2007 to July 2010 (Table I ). All patients and control subjects gave informed consent prior to sampling. The cross-sectional study protocol was reviewed and approved by the ethics committee of the All India Institute of Medical Sciences (AIIMS), New Delhi.
Detailed clinical history and findings were recorded in a case record form.
A total of 200 pulmonary TB (PTB) patients were enrolled prospectively from Comprehensive Rural Health Services Project (CRHSP), Centre for Community Medicine, Ballabgarh, Haryana (n=120) and Rajan Babu Institute for Pulmonary Medicine & Tuberculosis (RBIPMT), New Delhi (n=80); and were classified 78 category I PTB patients (new sputum smear positive), 42 category II PTB patients (sputum smear positive after default or relapse/treatment failure) and 80 multi-drug resistant PTB patients. Sputum (5-10 ml) and blood samples (2-3 ml) were collected within two weeks of initiation of antituberculosis treatment (ATT) from category I and category II patients (from CRHSP). MDR PTB patients admitted at RBIPMT were on ATT at the time of inclusion in the study. All the patients included in the study had the sputum culture positive for M. tuberculosis. After collection, samples were transported in cold chain.
Twenty one in-patients with tuberculous meningitis (TBM) were enrolled from the Department of Neurology, AIIMS, New Delhi. Sixteen patients were clinically and radiologically confirmed 12 and cerebrospinal fluid (CSF) of five patients grew M. tuberculosis on culture. Blood sample (2-3 ml) was collected within two weeks of initiation of ATT.
Thirty patients with tubercular pleural effusion were enrolled from CRHSP, Ballabgarh, Haryana and AIIMS, New Delhi. Patients were clinically and radiologically confirmed as the microbiological confirmation could not be obtained for all patients. A total of 60 subjects, who were suffering from respiratory/lung diseases (other than tuberculosis) were included as disease controls from AIIMS, New Delhi. Lung cancer (n=21), asthma (n=9), pneumonia (n=7), chronic obstructive pulmonary disorder (n=5), interstitial lung disease (n=3), sarcoidosis (n=3), respiratory distress (n=3), allergic broncho pulmonary aspergillosis (n=3), bronchiectasis (n=2), occupational lung disease (n=1), Wegener's granulomatosis (n=1), bronchiolitis obliterans (n=1), metabolic encephalopathy (n=1) formed the spectrum. Sputum/induced sputum samples were obtained. All above disease controls were evaluated bacteriologically for M. tuberculosis using culture and AFB smear and found negative. Forty six subjects had M. bovis BCG vaccination history. The purified protein derivative (PPD) status of the patients was unknown.
Thirty six healthy individuals (with no known history of active TB) were enrolled from the staff working in Department of Microbiology, AIIMS, New Delhi, as healthy controls or non-disease controls. All these were healthy with no apparent signs of any disease. All of them had BCG vaccination history. The purified protein derivative (PPD) status of the subjects was not known.
Sample processing: Sputum samples were processed using standard NALC-NaOH method 13 and smears were examined after Ziehl-Neelsen staining. Processed samples were inoculated in MGIT (Mycobacterial growth indicator tube) 960 non-radiometric automated isolation system (BD, USA). MGIT tube was supplemented with 0.5 ml of oleic acid-albumindextrose-catalase along with mixture of 5 antibiotics (PANTA i.e., polymyxin B, amphotericin B, nalidixic acid, trimethoprim and azlocillin) and 0.5 ml of decontaminated sample. M. tuberculosis complex and non-tuberculous mycobacteria were differentiated using p-nitrobenzoic acid (PNBA) test (as recommended in MGIT-960 protocol). Drug susceptibility testing (DST) was performed using 1 per cent proportion method using above automated culture system to reassure the MDR status (as recommended in MGIT-960 protocol). Serum samples were separated and immediately stored in -80°C till further use.
ELISA protocol: ELISA was performed with some modifications 14, 15 to estimate the humoral responses (IgG and IgA, in the same well) against native 16 kDa antigen. Briefly, the 96-well microtiter plates (Maxisorp Nunc, Denmark) were coated with native antigen in PBS (50 μl/well of 5 µg/ml) overnight at 4°C. Next day, plates were washed three times with PBS-T, blocked with 1 per cent BSA in PBS-T (blocking buffer) for two hours at 37°C and followed by three washings. Subsequently, 100 μl of diluted sera (1:100 in 0.1 x blocking buffer) from patients and healthy subjects was added and the plates were incubated for 90 min at 37°C. After six washes with PBS-Tween 20 (0.05% Tween 20 in PBS), a mixture of alkaline phosphatase-conjugated protein A (1:2,000) and anti-human immunoglobulin A (IgA; 1:1,000) (Sigma-Aldrich, St. Louis, USA) was added to each well and the plates were incubated for 1 h at 37°C. The wells were washed six times with PBS-T, and the bound enzyme-conjugated antibodies were detected with p-nitrophenylphosphate substrate (Sigma, USA), (1 mg/ml p-nitrophenylphosphate in 10% diethanolamine buffer containing 0.5 mM MgCl 2 , pH 9.8). The plates were read at 405 nm in ELISA plate reader (Microscan, ECIL, India).
Data analysis:
The cut-off was determined by calculating the mean optical density (OD) obtained with sera from healthy individuals plus 3 standard 
Results
The 347 subjects when grouped into different categories, 78 were in category I PTB, 42 were in category II PTB, 80 were MDR PTB, 21 were tubercular meningitis, 30 were pleural effusion, 36 were non-disease controls and 60 were disease controls (other than tuberculosis) ( Table I ). 16 kDa antigen was used for detection of humoral responses (IgG and IgA) in these subjects using ELISA and sensitivity, specificity and other parameters were predicted (Table II) . The diagnostic sensitivity of 16 kDa antigen with category I PTB, category II PTB and MDR PTB was found to be 80.7, 73.8 and 81.2 per cent, respectively. The sensitivity was found to be comparatively lower in category II PTB than the category I PTB and MDR PTB. While in the extra-pulmonary TB i.e. tuberculosis meningitis and tubercular pleural effusion cases, the diagnostic sensitivity was 42.8 and 63.3 per cent, respectively. Specificity was high (>94%) in PTB as well as extrapulmonary tuberculosis groups (Table II) .
None of the non-disease controls was positive for antibodies to 16 kDa, however, five disease controls were found to be positive. These patients were being treated for lung cancer (1), sarcoidosis (1), interstitial lung disease (ILD 1), pneumonia (1) and respiratory distress (1).
Discussion
In the present study, we evaluated the 16 kDa antigen, in PTB and EPTB (TBM and tubercular pleural effusion) patients, and compared the antibody assay with other diagnostic modalities. In our study, none of the non-disease controls was positive for antibodies to 16 kDa. In a TB endemic country like India a majority of the population is likely to be latently infected or BCG-vaccinated; the absence of any humoral response against mycobacteria gives credence to high specificity of the antigen for detecting active disease. A meta-analysis performed by Steingart et al 20 has reported high specificity for detection of pulmonary tuberculosis (86 to 100%), using the commercially available "pathozyme TB complex plus" (ELISA based antibody detection, utilizes the recombinant 38 kDa and 16 kDa) in various studies [21] [22] [23] . Another study has shown 98 per cent specificity in a large number of Polish population 24 using the above test. Raja et al 25 have shown a specificity of 94 per cent using 16 kDa antigen for antibody detection in pulmonary tuberculosis patients and controls including nontuberculous lung disease and healthy subjects. In non-tubercular disease controls, five of 60 controls gave the non-specific positive humoral response. Though sputum/induced sputum were obtained from above disease control group, all were negative for AFB smear microscopy and MGIT-960 rapid culture. All the care had been employed at the time of enrollment of above disease controls to rule out history of active TB. An earlier study 26 has shown that antibodies against 16 kDa do not cross-react with common environmental mycobacteria. Julian et al 21 have shown some non-specificity in pneumonia population using 16 kDa antibody detection, antibodies to 16 kDa have been shown among non-TB lung diseases such as asthma, lung cancer 25 . The loss of specificity may be due to latent infection or to nonspecific hyperglobulinaemia, common in bronchial diseases 27 .
Our results have shown a significant (P<0.05) higher antibody response in PTB than EPTB for 16 kDa antigen. Many of the serological studies have been reported from patients with extensive pulmonary disease 24, 28 . The group that would most benefit from serological tests is the one with smear negative or extrapulmonary TB. In this group of patients, the sensitivity of different assays was reported to be significantly lower than in the confirmed cases 9, 24, 29 . The extensive extra-cellular bacterial replication in cavities and the continued shedding of antigens is possibly enhanced in the pulmonary cavitary environment. The paucibacillary and often walled off EPTB lesions 30 may be different in producing lesser amount of antigen and hence may take longer to generate an antibody response. The study patients were sampled within a few days of the clinical diagnosis and hence may not have shown an adequate serological response.
The sensitivity was much higher in category I, category II PTB and MDR PTB patients. Repeated immune stimulation by mycobacterial antigens and higher antigenic load because of multiplying mycobacteria in MDR-PTB and category II PTB may explain this.
Serodiagnostic tests for tuberculosis have never been very successful due to suboptimal sensitivity and specificity. To discourage the rampant use of commercial TB serodiagnostics tests, WHO has issued a policy note discouraging the use of current serodiagnostics tests 31 .
The present study has limitations such as the serologic tests were performed retrospectively; using serum that had been stored at -80 o C, although no serum had been thawed more than once. The total number of EPTB (TBM and tubercular pleural effusion) subjects enrolled in the study was small. The results in our study were encouraging only in PTB group; and in tuberculous meningitis and tubercular pleural effusion patients were not up to expectations. The use of additional antigen(s) combinations or epitopes need to be evaluated for serodiagnosis.
